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Abstract
Genome-wide association studies have been successful in elucidating the genetic basis of 
colorectal cancer, but there remains unexplained variability in genetic risk. To identify new risk 
variants and to confirm reported associations, we conducted a genome-wide association study in 
1,701 colorectal cancer cases and 14,082 cancer-free controls from the Finnish population. A total 
of 9,068,015 genetic variants were imputed and tested, and 30 promising variants were studied in 
additional 11,647 cases and 12,356 controls of European ancestry. The previously reported 
association between the single-nucleotide polymorphism rs992157 (2q35) and colorectal cancer 
was independently replicated (p=2.08×10−4; OR, 1.14; 95% CI, 1.06–1.23), and it was genome-
wide significant in combined analysis (p=1.50×10−9; OR, 1.12; 95% CI, 1.08–1.16). Variants at 
2q35, 6p21.2, 8q23.3, 8q24.21, 10q22.3, 10q24.2, 11q13.4, 11q23.1, 14q22.2, 15q13.3, 18q21.1, 
20p12.3, and 20q13.33 were associated with colorectal cancer in the Finnish population (false 
discovery rate <0.1), but new risk loci were not found. These results replicate the effects of 
multiple loci on the risk of colorectal cancer and identify shared risk alleles between the Finnish 
population isolate and outbred populations.
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Introduction
Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 
approximately 10% of global cancer incidence and mortality (http://globocan.iarc.fr/). 
Numerous genetic loci have been associated with CRC in genome-wide association studies 
(GWASs; https://www.ebi.ac.uk/gwas/), but much of its heritability remains unexplained, 
which limits personalized risk assessment and biological understanding of the disease.1,2 
Discovery of new loci and replication of previously reported associations is thus important, 
and recent studies have continued to reveal novel CRC risk variants.3–7 The genetic 
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architecture of CRC varies between populations, and studies in isolated founder populations 
can offer valuable insights into disease susceptibility.8
We conducted a GWAS of CRC in the Finnish population (the FIN cohort) using a large 
publicly available reference panel to impute genotypes and thus increase the odds of 
identifying disease-associated alleles across a wide range of allele frequencies.9 Thirty 
promising variants were investigated further in 11 European-ancestry studies (STHLM2, 
Gothenburg, HUNT, Estonia, FINRISK, COIN, UK1, Scotland1, VQ58, CCFR1, and 
CCFR2), adding to a total of 13,348 CRC cases and 26,438 controls.
In a recent meta-analysis of GWASs, the single-nucleotide polymorphism (SNP) rs992157 at 
2q35, intronic to PNKD and TMBIM1, was found to be associated with CRC (p=3.15×10−8; 
odds ratio (OR), 1.10; 95% confidence interval (CI), 1.06–1.13).6 To replicate this finding, 
we genotyped and analyzed rs992157 in 4,439 CRC cases and 15,847 controls from five 
Northern European cohorts (STHLM2, Gothenburg, HUNT, Estonia, and a subset of the FIN 
cohort) that had not been previously studied for the association between rs992157 and CRC.
Materials and methods
This study was conducted in accordance with the Declaration of Helsinki and approved by 
the Finnish National Supervisory Authority for Welfare and Health, National Institute for 
Health and Welfare (THL/151/5.05.00/2017), and the Ethics Committee of the Hospital 
District of Helsinki and Uusimaa (HUS/408/13/03/03/09). We derived 1,627 cases with 
colorectal adenocarcinoma from the ongoing Finnish CRC collection and genotyped normal 
tissues (colorectal tissue or blood) with Illumina (San Diego, CA) HumanOmni2.5–8 SNP 
arrays.10,11 Illumina HumanCoreExome SNP array data for additional 91 CRC patients and 
14,187 Finnish cancer-free controls were obtained from the National FINRISK Study 
(https://www.thl.fi/fi/web/thlfi-en/research-and-expertwork/population-studies/the-national-
finrisk-study). Data on diagnosed cancers in the FINRISK study participants were collected 
from the Finnish Cancer Registry. PLINK v.1.90b3i (www.cog-genomics.org/plink/1.9/) was 
used for quality control.12 A total of 122 samples (17 genotyped with the HumanOmni2.5–8 
array and 105 genotyped with HumanCoreExome array) were excluded on the basis of close 
relatedness (identity-by-descent coefficient >0.2), duplication, discordant sex information, or 
low genotyping rate. The FIN cohort consisted of the remaining 1,701 CRC cases and 
14,082 cancer-free controls. By design, the HumanOmni2.5–8 SNP array contained 
2,315,673 autosomal sites, 273,074 of which overlapped with the HumanCoreExome SNP 
array (https://support.illumina.com/downloads.html). Exclusion criteria for SNPs were 
genotyping rate <95%, excess homozygosity (frequency of rare homozygotes exceeding the 
frequency of heterozygotes, or any rare homozygous genotype with minor allele frequency 
(MAF) <2%), deviation from the Hardy-Weinberg equilibrium (p<1×10−8), differential 
missingness between genotyping batches (p<1×10−8), differential patterns of linkage 
disequilibrium (LD) in cases versus controls, and LD-based strand inconsistency. After 
quality control, 214,705 SNPs were pre-phased with SHAPEIT v2 (r790), and genotypes 
were imputed with a publicly available reference panel (https://imputation.sanger.ac.uk/; 
http://www.haplotype-reference-consortium.org/).9 Variants with low allele frequency 
(<0.4%) or low IMPUTE2 info score (<0.4) were excluded prior to association analysis. In 
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stage 1, disease associations were tested with a linear mixed model (BOLT-LMM-inf; 
https://data.broadinstitute.org/alkesgroup/BOLT-LMM/), adjusting for log-transformed age 
and sex.13 A linear mixed model was used because it can control for population structure 
and cryptic relatedness.14 The age covariate was defined as age at CRC diagnosis in cases 
and age at right censoring (end of follow-up or death) in controls. An additive genetic model 
was assumed. The genomic inflation factor was estimated by dividing the observed median 
of the BOLT-LMM-inf test statistic by the median of the chi-squared distribution with one 
degree of freedom. The Benjamini-Hochberg method was used to adjust for false discovery 
rate.
In stage 2, the MassARRAY System by Agena Bioscience (San Diego, CA) was utilized at 
the Institute for Molecular Medicine Finland (FIMM) to genotype single-nucleotide variants 
in Nordic cohorts (STHLM2, 544 cases/541 controls; Gothenburg, 1,903 cases/258 controls; 
HUNT, 1,168 cases/1,147 controls; Estonia, 257 cases/259 controls; and FINRISK, 198 
cases/172 controls), as well as 1,038 individuals from the FIN cohort who had also been 
genotyped with SNP arrays (925 with the HumanOmni2.5–8 array and 113 with the 
HumanCoreExome array). The STHLM2 cohort consisted of men who had been referred to 
prostate-specific antigen screening in Stockholm County, Sweden between 2010 and 2012; 
DNA samples were provided by the Karolinska Institute Biobank (http://ki.se/forskning/ki-
biobank). The Gothenburg cohort was formed from CRC patients who had been operated at 
the Sahlgrenska University Hospital, Gothenburg, Sweden; DNA samples from cases and 
controls were provided by the Sahlgrenska Biobank (https://www.gothiaforum.com/sab). 
DNA samples from the HUNT cohort were provided by the Norwegian Nord-Trøndelag 
Health Study (HUNT) and Biobank (https://www.ntnu.edu/hunt). The Estonia cohort was 
derived from the sample collections of the Estonian Genome Center (www.geenivaramu.ee/
en). The FINRISK cohort consisted of participants of the National FINRISK Study (198 
CRC cases and 172 cancer-free controls) who had not been included in the FIN cohort due 
to unavailable SNP array data; DNA samples were provided by the THL Biobank, Finland 
(https://www.thl.fi/fi/web/thlfi-en/topics/information-packages/thl-biobank). When possible, 
cancer-free controls were matched to CRC cases on year of birth and sex. To assess 
imputation accuracy, squared Pearson correlation coefficients (r2) between IMPUTE2 
genotype dosage and MassARRAY genotype were calculated.
To enable standard meta-analysis, data from the FIN cohort were reanalyzed by 
unconditional logistic regression under an additive genetic model, adjusting for sex, log-
transformed age, and 10 principal components (SNPTEST v.2.5.2). In the MassARRAY-
genotyped Nordic cohorts, unconditional logistic regression was applied using R v.3.3.3, 
provided that at least 10 minor alleles were observed. Details of the previously published 
GWASs (COIN, UK1, Scotland1, VQ58, CCFR1, and CCFR2) can be found in Reference 
15.15 Genomic control was applied by multiplying the standard errors of regression 
coefficients by the square root of the inflation factor of the respective study. PLINK v.
1.90b3i was used for LD-based SNP pruning and principal component analysis (PCA). PCA 
was performed using 13,012 LD-pruned SNPs with allele frequency >5% and IMPUTE2 
info score >0.9. R v.3.3.3 was used for meta-analysis. Estimated log ORs and standard errors 
were combined to obtain summary p-values, ORs, and 95% CIs under inverse-variance 
weighted random-effects and fixed-effect models (function “rma.uni” in the metafor package 
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v.1.9–9). All reported p-values are two-sided. The type I error rate (α) was 0.05, 
corresponding to a genome-wide significance threshold of 5×10−8.
Results
In stage 1, we used a linear mixed model (BOLT-LMM-inf)13 to test 9,068,015 single-
nucleotide variants for association with CRC in the FIN cohort, which comprised 1,701 
Finnish CRC cases and 14,082 population-matched, cancer-free controls. The median of the 
BOLT-LMM-inf test statistic was 0.512, corresponding to an inflation factor of 1.12, which 
was used for genomic control. A quantile-quantile (Q-Q) plot is shown in Supplementary 
Figure 1, PCA plots in Supplementary Figures 2 and 3, and a Manhattan plot in 
Supplementary Figure 4. A low-frequency variant at 12q14.3 (rs73121704; MAF, 0.860%) 
displayed the smallest p-value in stage 1 (p=4.07×10−9). Among the highest-ranking SNPs 
were the CRC-associated variants rs10505477 (p=5.29×10−8), rs6589219 (p=4.34×10−7; r2 
with rs3802842, 0.942 in 1,000 Genomes Phase 3 European populations), and rs6983267 
(p=1.38×10−6).16–18 Thirty-eight previously published CRC risk SNPs were tested for 
association with CRC in the FIN cohort, and 14 of the 38 SNPs showed associations with 
false discovery rate <0.1. Directions of effects were consistent with earlier publications for 
each of the 14 SNPs, which were located at 11q23.1 (rs3802842, q=1.77×10−5), 8q24.21 
(rs6983267, q= 1.77×10−5; rs7014346, q=1.77×10−5), 20p12.3 (rs961253, q=6.92×10−5), 
15q13.3 (rs4779584, q=1.29×10−3), 10q22.3 (rs704017, q=1.91×10−3), 18q21.1 (rs4939827, 
q=7.96×10−3), 2q35 (rs992157, q=7.96×10−3), 8q23.3 (rs16892766, q=0.0113), 14q22.2 
(rs4444235, q=0.0231), 6p21.2 (rs1321311, q=0.0231), 20q13.33 (rs4925386, q=0.0501), 
10q24.2 (rs1035209, q=0.0536), and 11q13.4 (rs3824999, q=0.0604). Stage 1 results and 
LocusZoom plots (http://locuszoom.org/) are shown in Supplementary Tables 1 and 2 and in 
Supplementary Figures 35 to 102, respectively.
From 20 loci that were ranked highest in stage 1, we selected 40 variants for MassARRAY 
genotyping in five Nordic cohorts (STHLM2, Gothenburg, HUNT, Estonia, and FINRISK; 
stage 2). Two variants were selected from each locus. rs992157 (2q35) was also selected for 
stage 2 because it had been recently reported as a CRC risk factor. We were unable to design 
genotyping assays for seven variants because of sequence context, and four variants failed 
genotyping. Consequently, 30 variants representing 20 loci were successfully genotyped in a 
total of 4,070 Nordic CRC cases and 2,377 controls. The MAF of 6:73457627G>C was low 
in all five Nordic cohorts, ranging from 0.000923 to 0.00954 (allele count, 2–7). To evaluate 
imputation accuracy, 1,038 individuals from the FIN cohort were directly genotyped with 
the MassARRAY platform. Squared Pearson correlation coefficients (r2) between IMPUTE2 
genotype dosage and MassARRAY genotype for the 30 variants ranged from 0.816 to 1.00 
(median, 0.978).
In stage 3, we obtained summary statistics from previously published GWASs that 
comprised 7,577 CRC cases and 9,979 controls of European ancestry.15 Summary-level data 
were available for 27 of the 30 variants that were genotyped in stage 2 (data for 
rs150509351, rs186867472, and 6:73457627G>C were missing).
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To increase statistical power, datasets from stages 1 to 3 were combined (Figure 1), totaling 
13,348 CRC cases and 26,438 controls.19 The FIN cohort was reanalyzed by logistic 
regression to obtain log ORs and corresponding standard errors; the inflation factor was 
1.11. The post-imputation inflation factors for the COIN, UK1, Scotland1, VQ58, CCFR1 
and CCFR2 studies were 1.10, 1.03, 1.04, 1.04, 1.03, and 1.08, respectively.15 Genomic 
control was applied for each of these studies. Inflation factors for the STHLM2, Gothenburg, 
HUNT, or Estonia studies were not estimated because of the small number of genotyped 
markers. Fixed-effect meta-analysis was performed, but because of possible study 
heterogeneity, we considered the random-effects model (Supplementary Table 3). Under the 
random-effects model, rs10505477 (8q24.21), rs6983267 (8q24.21), and rs992157 (2q35) 
were genome-wide significant (for rs10505477, p=7.63×10−14, phet=0.144, I2=34.4%; for 
rs6983267, p=7.45×10−13, phet=0.0985, I2=37.7%; for rs992157, p=1.50×10−9, phet=0.777, 
I2=0%), and rs6589219 (11q23.1) displayed suggestive evidence of association 
(p=9.14×10−6, phet=0.153, I2=36.5%). Combined effect size estimates and directions of 
effects for these four SNPs were consistent with prior studies.6,16–18
Next, we studied rs992157 (2q35) in a replication dataset comprising 4,439 CRC cases and 
15,847 controls (STHLM2, Gothenburg, HUNT, Estonia, and a subset of the FIN cohort) 
who had not been previously studied for the association between rs992157 and CRC (Figure 
2). In the FIN cohort, rs992157 had been directly genotyped with SNP arrays in both cases 
and controls, and the other Nordic cohorts were genotyped with the MassARRAY platform. 
Logistic regression models were fit within each cohort. In the independent subset of the FIN 
cohort (567 CRC cases and 13,642 cancer-free controls), the inflation factor was 1.11, and 
genomic control was applied accordingly. Estimated log ORs were combined under random-
effects and fixed-effect models, the results of which were highly similar without notable 
study heterogeneity (phet=0.462, I2=0%). Applying Bonferroni correction for the 30 variants 
that were genotyped in the MassARRAY experiment (α=0.05/30≈0.00167), rs992157 was 
significantly associated with CRC with an OR of 1.14 (95% CI, 1.06–1.23; p=2.08×10−4). 
Consistent with prior results, the alternative allele (A) conferred a higher risk of CRC than 
the reference allele (G). For rs992157, r2 between IMPUTE2 genotype dosage and 
MassARRAY genotype was 1.00 in the FIN cohort.
Discussion
The identification of CRC susceptibility alleles and quantification of their effects is 
biologically and clinically meaningful. The genome-wide statistical analysis of tag SNPs has 
highlighted new genes and regulatory mechanisms in the pathogenesis of CRC while 
concurrently allowing more accurate estimation of the personalized risk of colorectal 
neoplasms.20,21 We conducted a GWAS of CRC in the Finnish population (stage 1), 
genotyped 30 promising variants in five Nordic cohorts (stage 2), and analyzed 
corresponding summary statistics from previously published GWASs (stage 3). A total of 
39,786 individuals (13,348 CRC cases and 26,438 controls) were analyzed in stages 1 to 3. 
New genotype data generated in this study were used to analyze the recently reported effect 
of rs992157 (2q35) on CRC risk.
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The association between rs992157 and CRC was independently replicated (p=2.08×10−4), 
and its effect size was approximately 1.1 (OR, 1.14; 95% CI, 1.06–1.23). In the combined 
analysis of 13,348 CRC cases and 26,438 controls, the p-value and OR for rs992157 were 
1.50×10−9 and 1.12 (95% CI, 1.08–1.16), respectively, with no indication of study 
heterogeneity (phet=0.777, I2=0%). In addition to CRC, rs992157 has shown pleiotropic 
effects on adult human height and inflammatory bowel disease.6,22
In stage 1, we found evidence supporting multiple previously published SNPs as risk factors 
for CRC in the Finnish population with false discovery rate <0.1. The corresponding 
chromosomal regions and nearby genes were 2q35 (PNKD and TMBIM1), 6p21.2 
(TRNAI25), 8q23.3 (LINC00536 and EIF3H), 8q24.21 (CCAT2 and LOC101930033), 
10q22.3 (ZMIZ1-AS1), 10q24.2 (NKX2–3 and SLC25A28), 11q13.4 (POLD3), 11q23.1 
(COLCA1 and COLCA2), 14q22.2 (RPS3AP46 and MIR5580), 15q13.3 (SCG5 and 
GREM1), 18q21.1 (SMAD7), 20p12.3 (FGFR3P3 and CASC20), and 20q13.33 (LAMA5).
We did not find Finnish population-specific CRC risk variants, which may reflect limitations 
in replicating them in other populations, their rarity, or small contributions to inherited risk. 
A low-frequency variant at 12q14.3 (rs73121704; MAF, 0.860%) displayed a notable 
association in stage 1 (p=4.07×10−9), but the finding was not supported by meta-analysis 
(random-effects p=0.466, fixed-effect p=0.122). Bias due to genotype imputation or 
population stratification remains a concern, and further data is needed.
A limitation of the study is that the number of variants selected for stages 2 and 3 was 
relatively small, and disease-associated variants may have been omitted from further 
investigation because of low rank in the primary analysis. It is also difficult to assess 
whether there was residual confounding due to population stratification or different 
genotyping platforms. For rs992157, r2 between IMPUTE2 genotype dosage and 
MassARRAY genotype was 1.00, making technical bias unlikely. Genomic control was 
applied for all primary GWASs to avoid type I error.
In conclusion, we replicated the association between rs992157 (2q35) and CRC in Northern 
European studies and found it to be genome-wide significant in a meta-analysis of 12 
European-ancestry studies. SNPs at 2q35, 6p21.2, 8q23.3, 8q24.21, 10q22.3, 10q24.2, 
11q13.4, 11q23.1, 14q22.2, 15q13.3, 18q21.1, 20p12.3, and 20q13.33 were associated with 
CRC in the Finnish population, which validates findings from previous studies and reveals 
shared genetic architecture of CRC between the Finnish population isolate and outbred 
populations.
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Novelty & impact statements
This study provides strong evidence for the association between rs992157 (2q35) and 
colorectal cancer by independent replication in 4,439 cases and 15,847 controls, as well 
as meta-analysis of 39,786 European-ancestry individuals. Previously published SNPs at 
2q35, 6p21.2, 8q23.3, 8q24.21, 10q22.3, 10q24.2, 11q13.4, 11q23.1, 14q22.2, 15q13.3, 
18q21.1, 20p12.3, and 20q13.33 were associated with colorectal cancer in the Finnish 
population, but new risk loci were not identified.
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Figure 1. 
Study scheme. Sources of genetic markers are shown on the left, analytic stages in the 
center, and sources of samples on the right.
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Figure 2. 
Study cohorts, sample sizes, and estimated odds ratios for rs992157. The vertical line 
corresponds to the null hypothesis (odds ratio=1). The horizontal lines and square brackets 
indicate 95% confidence intervals. Areas of the boxes are proportional to the weight of the 
study. Diamonds represent combined estimates. FE, fixed-effect. RE, random-effects.
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